The Icahn School of Medicine at Mount Sinai has received a $4.6 million gift from The Pershing Square Foundation to support women’s health research and advance careers for female scientists
“Mount Sinai Fuster Heart Hospital” furthers vision of world-leading cardiac care and research that prevents heart disease worldwide
A Mount Sinai-led team of researchers has shed new light on the ways in which cocaine addiction dysregulates the normal function of dopamine neurons and thus the brain’s ability to process and respond to reward-related information, making it more difficult for individuals to change their addictive behaviors.
Mount Sinai researchers have discovered a link between certain per- and polyfluoroalkyl substances (PFAS) and an increased risk for thyroid cancer.
A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer. The results were simultaneously reported in The New England Journal of Medicine and at the annual meeting of the European Society for Medical Oncology.
Oula-Mount Sinai West partnership offers patients the best of obstetrics and midwifery, with midwife-led delivery supported by leading hospital's expertise and resources
CastleVax, a clinical stage vaccine platform company, has received a Project NexGen award valued at up to $338 million from the Biomedical Advanced Research and Development Authority (BARDA), to support the development of a next-generation, booster vaccine to protect against COVID-19 for years to come.
The Mount Sinai Health System has received a $12,180,625 grant from the National Heart, Lung and Blood Institute to compare new treatment options for sickle cell disease and determine which work best for specific patients.
Researchers at the Icahn School of Medicine at Mount Sinai and the University of California San Diego have been awarded an $8.5 million grant to create a data integration hub aimed at accelerating novel therapeutics and cures for diseases within initiatives supported by the National Institutes of Health (NIH) Common Fund.
New method measures age acceleration, opening doors to unlocking genetic and environmental risk for cognitive disorders and Alzheimer’s
Models built on machine learning in health care can be victims of their own success, according to researchers at the Icahn School of Medicine and the University of Michigan.
Miriam Merad, MD, PhD, an esteemed immunologist at the Icahn School of Medicine at Mount Sinai, has been elected to the National Academy of Medicine (NAM) in recognition of her pioneering contributions to the fields of immunology and cell biology.
Agreement aims to help make clinical trials more efficient and lead to faster advances in patient care
Today, the Mount Sinai Health System, New York City’s largest academic medical system, announced the opening of its new Discovery and Innovation Center with a ceremonial ribbon cutting. This state-of-the-art research lab will expand research capabilities in collaboration with clinical neuroscience and neurosurgery centers of excellence at Mount Sinai West.
For the third time, the Icahn School of Medicine at Mount Sinai has earned the American Medical Association (AMA) Joy in Medicine™ distinction.
Mount Sinai investigators have developed a new approach for treating invasive bladder cancer without the need for surgical removal of the bladder, according to a study published in Nature Medicine in September.
Top rankings include Mount Sinai Morningside and The Mount Sinai Hospital, with stroke rehabilitation a standout program
Michael F. Murray, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, has been named the new System Chief of the Division of Genomic Medicine and the Clinical Director of the Institute for Genomic Health at Mount Sinai.
Researchers at the Icahn School of Medicine at Mount Sinai have been awarded a $10.2 million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to investigate risk factors for malignant arrhythmias in mitral valve prolapse.
Research conducted at Mount Sinai and Yale confirms long COVID is a biological disease by showing blood biomarkers that can predict who has it
In a study published online in CELL today, scientists at UCSF QBI, University College London and the Icahn School of Medicine at Mount Sinai reported breakthrough findings on convergent evolutionary mechanisms shared by COVID-19 variants, allowing them to overcome both adaptive and innate immune system barriers.
Seventy-five years after pioneering doctors at The Mount Sinai Hospital conducted the first hemodialysis treatment in the United States, the hospital is marking progress to date in a continuing medical education (CME) event on Monday, October 2. The event will be led by innovators in the field of nephrology.
New research from Mount Sinai identifies key molecules in blood and nasal passages that play a pivotal role in asthma development and progression
A team of leading clinicians, engineers, and neuroscientists has made a groundbreaking discovery in the field of treatment-resistant depression.
First systematic study of the subject finds that more than half of unsalaried community health care workers in dual-cadre programs experienced unfair treatment in the workplace
Mount Sinai study focused on Harlem preschools emphasizes the need for specialized health promotion programs in classrooms starting at an early age
The Icahn School of Medicine at Mount Sinai has agreed to an exclusive license option with GNOMX Corp. (GNOMX) for epigenetic diagnostic and prognostic technology for infectious diseases.
$13 million will fund a multidisciplinary, multi-institution team effort to develop stronger and more versatile vaccines
The National Cancer Institute has awarded the Icahn School of Medicine at Mount Sinai a $3.4 million grant to create a model that identifies the best prostate cancer treatment for people with HIV.
New method can predict risks of cardiovascular disease, mortality in sleep apnea patients
Researchers at the Icahn School of Medicine at Mount Sinai have identified the structure of a special transporter found in red blood cells and how it interacts with drugs.
Agreement aims to improve patient care and outcomes on a global scale
Insights could impact approach to managing and preventing condition in children.
Results from a large-scale clinical trial could increase usage of high resolution imaging for guiding interventional coronary procedures
Asian Americans have significantly higher exposure than other ethnic or racial groups to PFAS, a family of thousands of synthetic chemicals also known as “toxic forever” chemicals, Mount Sinai-led researchers report.
Mount Sinai study identifies most effective and safest outpatient labor induction methods, potentially reducing hospital stays and increasing hospital efficiency in use of resources
The Mount Sinai Health System was recognized today as an outstanding health care employer in New York, ranking in the top 15 on the prestigious Forbes list of “America’s Best-in-State Employers.”
Mount Sinai study among the first to show that drugs targeting the lung, rather than bacteria, may prevent staph infection in flu patients
Mount Sinai Health System announces a multi-year renewal of an exclusive partnership with the United States Tennis Association (USTA)
The best heart rate for burning fat differs for each individual and often does not align with the “fat burning zone” on commercial exercise machines, Icahn School of Medicine at Mount Sinai researchers report. Instead, the researchers said, clinical exercise testing—a diagnostic procedure to measure a person’s physiological response to exercise—may be a more useful tool to help individuals achieve intended fat loss goals. The study, which used a machine learning-based modeling approach, was published online today in Nutrition, Metabolism and Cardiovascular Disease.
Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai and colleagues have identified a 64-protein signature that may predict a subset of ovarian cancer patients who are unlikely to respond to chemotherapy. The multicenter study, published online August 3 in Cell, reports on a pioneering analysis of chemo-refractoriness in high-grade serous ovarian cancer (HGSOC). The work also implicates possible therapeutic targets for these patients.
The cardiovascular polypill, developed by the Spanish National Centre for Cardiovascular Research (CNIC) and the pharmaceutical company Ferrer, has been included by the World Health Organization (WHO) in its List of Essential Medicines.
The Mount Sinai Medical Legal Partnership (MSMLP), which provides legal aid to Mount Sinai Health System patients in need, has launched a clinic to help breast cancer patients navigate legal issues that arise due to their diagnoses.
Human cells are constantly communicating, and some cells, particularly in cancer, are master manipulators, using these communications channels to persuade innocent bystander cells to collude and participate in tumor growth.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right